The rates of metachronous CRC were also higher in these individuals (15.5 and 23.2% in MLH1 and MSH2 vs. 10.0 and 5.9% in MSH6 and PMS2, respectively) (Table 2). This evidence concerns the gene PMS2 and colorectal carcinoma.